TL;DR
- 1.SS-31 (elamipretide) received FDA accelerated approval as Forzinity in September 2025 for Barth syndrome, making it the only FDA-approved compound in this stack.
- 2.A 2025 study in Biogerontology found Epithalon increased telomerase activity 26-fold in normal human epithelial cells in laboratory conditions, the first independent Western replication of the Russian findings.
- 3.GHK-Cu and Epithalon were removed from FDA Category 2 in April 2026 and are now in regulatory gray-zone status heading to PCAC review.
- 4.The three peptides target distinct aging mechanisms and do not compete with each other. Sequencing them matters more than running them simultaneously.
- 5.Run GHK-Cu continuously as a base layer, Epithalon in 10-day pulses four times a year, and SS-31 in two focused 6-8 week cycles annually.
On September 19, 2025, the FDA approved elamipretide, sold as Forzinity, as the first mitochondria-targeted therapeutic in US history. That makes SS-31 the only FDA-approved drug in the GHK-Cu, Epithalon, and SS-31 anti-aging stack. Most people running this protocol do not know that. It also means the legal path to sourcing it changed significantly, and not in the direction most people expect.
At the same time, a 2025 study in Biogerontology independently confirmed that Epithalon increased telomerase activity 26-fold in normal human epithelial cells under laboratory conditions. That is the first replication of Khavinson's original Russian findings by a Western research group. And GHK-Cu, after years on the FDA compounding ban list, was removed from Category 2 in April 2026 and is now heading toward a PCAC hearing. This stack is moving fast. Here is where each peptide stands, what the evidence actually shows, and the 12-week protocol that sequences all three correctly.
Increase in telomerase activity in normal human epithelial cells treated with Epithalon in a 2025 Biogerontology study (Al-dulaimi et al., PMC12411320). This is in vitro data from cell cultures, not a human trial, but it is the strongest independent confirmation of Epithalon's mechanism published to date.
The reason to stack these three peptides is that each one targets a completely different aging mechanism. GHK-Cu works at the gene expression level, reactivating tissue repair pathways that get progressively silenced as you age. Epithalon works at the telomere level, activating telomerase to rebuild the protective caps on your DNA that shorten with every cell division. SS-31 works at the mitochondrial level, binding cardiolipin on the inner mitochondrial membrane to restore ATP output that declines as the membrane oxidizes over decades.
These pathways do not overlap. Running all three addresses the three best-documented molecular mechanisms of biological aging at the same time, without redundancy. The challenge is sequencing them correctly, because each peptide has a different optimal cycle structure.
Think of aging as three clocks running simultaneously. Clock one tracks your gene expression: over time, the repair genes that kept your tissues young get progressively switched off. Clock two tracks your telomeres: every cell division trims the protective caps on your DNA until cells stop dividing entirely. Clock three tracks your mitochondria: the energy factories in your cells gradually lose output as their membranes oxidize. GHK-Cu resets clock one. Epithalon works on clock two. SS-31 targets clock three. Each clock needs a different tool because each runs on a different mechanism.
What Makes GHK-Cu the Base Layer of Every Anti-Aging Stack?
GHK-Cu is a naturally occurring copper-binding tripeptide that circulates in human blood plasma. Healthy adults in their twenties have plasma concentrations around 200 nanograms per milliliter. By age 60, that number has dropped to roughly 80, a 60 percent decline. That decline tracks closely with the progressive silencing of repair genes across virtually every tissue type.
The 2018 analysis by Pickart and Margolina in the International Journal of Molecular Sciences is the benchmark reference. They mapped GHK-Cu's gene expression effects using the NCBI Gene Expression Omnibus database and found it modulates over 4,000 human genes. Those genes cover collagen synthesis, antioxidant defense, anti-inflammatory regulation, neurotrophin signaling, and dozens of tissue repair pathways. No other single compound in the longevity space has been shown to touch this many aging-relevant gene networks.
"GHK is a naturally occurring plasma tripeptide that declines with age. It has the ability to promote wound healing, attract immune cells, foster blood vessel growth, and activate a broad regenerative program across human tissues."
Pickart and Margolina, International Journal of Molecular Sciences, 2018
A 2024 paper by Sarbaziha and Goldberg in PRIME Journal confirmed GHK-Cu increased collagen deposition in 70 percent of participants versus 50 percent for vitamin C and 40 percent for placebo at one month. A separate 2024 PubMed-indexed study (PMID 38879894) showed GHK-Cu reduced lung inflammation and fibrosis markers in a silicosis model by targeting peroxiredoxin 6, a key antioxidant enzyme in pulmonary tissue. The lung data points to systemic effects well beyond skin repair.
Why GHK-Cu Is Not Just a Skin Peptide
The cosmetics industry adopted GHK-Cu decades ago, which created the widespread perception that this is primarily a skin compound. That framing is wrong in a way that systematically undersells the peptide. The Pickart 2018 analysis showed GHK-Cu's gene modulation occurs in cardiac muscle, lung tissue, neural tissue, and liver cells, not just skin fibroblasts. The skin results are the most visible, which is why the consumer market went that direction. The systemic effects on gene expression are arguably more significant for longevity.
The practical implication: GHK-Cu works best as a continuous base layer, not a cycle compound. Unlike growth hormone secretagogues, there is no evidence of receptor downregulation with extended use. Most longevity protocols run it at 1-3 mg per day subcutaneously, or as a 0.25-1 percent topical concentration for skin-specific applications. The gene modulation effects appear to require sustained exposure rather than pulsed cycles.
GHK-Cu Regulatory Update: April 2026 Gray Zone
Injectable GHK-Cu was placed in FDA Category 2 (banned from compounding) in September 2023. On April 22, 2026, the FDA removed it from Category 2 following nominator withdrawals. Removal from Category 2 does not mean compounding is authorized. Injectable GHK-Cu is now in a regulatory gray zone, with PCAC review scheduled before February 2027. Topical GHK-Cu has always been permissible under cosmetics regulations and remains so. For the injectable form, a physician at a licensed compounding pharmacy with documented clinical justification is the appropriate path until that PCAC hearing resolves its status.
Collagen synthesis
Activates COL1A1, COL3A1, and related collagen genes. Direct tissue repair in skin, tendons, and connective tissue.
Antioxidant defense
Upregulates SOD, catalase, and NRF2 pathway genes. Reduces oxidative damage across tissue types including lung and cardiac muscle.
Anti-inflammatory
Suppresses NF-kB and inflammatory cytokine pathways. Relevant for the chronic low-grade inflammation that accelerates aging.
Gene reactivation
Reactivates repair genes that become progressively silenced with age. The 4,000-gene analysis suggests this may be its most significant longevity mechanism.
| GHK-Cu Route | Dose or Concentration | Protocol | FDA Status (June 2026) |
|---|---|---|---|
| Topical serum | 0.25-1% | Daily, no cycle required | Permitted under cosmetics regulations |
| Subcutaneous injection | 1-3 mg/day | Continuous or 3-6 month cycles | Gray zone: removed from Category 2 in April 2026, PCAC review pending before Feb 2027 |
| Nasal (experimental) | 0.25-0.5 mg per application | Split daily dose | No defined regulatory pathway |
How Epithalon Extends Telomeres (And What the 2025 Independent Study Actually Found)
For three decades, almost all Epithalon research came from one institution: the St. Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson. The single-source problem was the main reason Western researchers remained skeptical. In 2025, that changed. Al-dulaimi, Thomas, Matta, and Roberts published a study in Biogerontology (PMC12411320) independently confirming that Epithalon activated telomerase in normal human cell lines: a 4-fold increase in fibroblasts and a 26-fold increase in normal epithelial cells. This was done in cell cultures, not in human subjects, but it validated the core mechanism for the first time outside Russia.
The finding matters because of what telomerase does. Normal somatic cells, the cells that make up most of your body, have almost no telomerase activity. Every time a cell divides, the telomeres shorten slightly. After 50-70 divisions, cells reach the Hayflick limit and stop dividing. That cellular senescence is one of the primary drivers of tissue aging. Epithalon appears to temporarily reactivate the enzyme responsible for rebuilding those shortening caps. A 2025 review by Araj et al. in International Journal of Molecular Sciences (PMC11943447) also documented a human circadian study in 75 women showing 1.6-fold enhanced melatonin synthesis with 20-day sublingual Epithalon, alongside a retinitis pigmentosa trial in 162 patients showing improved visual acuity and visual field expansion.
The Paradox: Epithalon Activates a Cancer Enzyme and Reduces Tumors Anyway
Here is the uncomfortable fact most Epithalon protocol guides skip: telomerase is how cancer cells become immortal. Tumor cells hijack telomerase to escape the Hayflick limit and keep dividing indefinitely. Activating telomerase in healthy cells uses the same enzyme. The obvious concern is that you might accelerate cancer risk while pursuing anti-aging benefits.
That is not what the Russian animal studies found. Khavinson's long-term studies in cancer-prone mouse models consistently showed Epithalon-treated animals developed fewer tumors, later in life, with slower progression. The 2025 IJMS review examined this paradox and proposed two mechanisms: Epithalon may improve immune surveillance that clears early malignant transformations alongside telomerase activation, and it may work through epigenetic gating of the hTERT promoter in a way that differs from the uncontrolled activation seen in cancer cells. This is not settled science. No long-term human safety randomized controlled trial exists. But the animal data is consistent enough across multiple studies that the theoretical cancer concern has not materialized in the preclinical evidence available.
Epithalon Regulatory Update: PCAC Hearing July 24, 2026
Epithalon was placed in FDA Category 2 in September 2023 and removed from it in April 2026. It is now scheduled for PCAC review on July 24, 2026, as part of a two-day hearing that also covers BPC-157, TB-500, and Semax. Epithalon is being evaluated specifically for a potential insomnia indication, reflecting the documented melatonin pathway effects from the human circadian data. A favorable PCAC vote would initiate formal rulemaking to add it to the 503A Bulk Drug Substances list. That hearing is five weeks away from this article's publication date. If you have been waiting for a clearer legal access path to Epithalon in the US, July 24 is the date to watch.
Years of continuous Epithalon research at the St. Petersburg Institute of Bioregulation and Gerontology, the longest institutional peptide research program of its kind. The dataset spans multiple species, and the 2025 Biogerontology paper is the first independent Western confirmation that the core telomere mechanism is real.
| Epithalon Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Standard | 5-10 mg/day subQ | 10 consecutive days | 2-4 cycles per year. First cycle often produces the strongest response. |
| Extended (Khavinson protocol) | 5 mg/day subQ | 20 consecutive days | Used in original Russian institutional protocols for longevity applications. |
| Sublingual (circadian/sleep focus) | 0.5 mg/day | 20 consecutive days | Route used in the melatonin study; lower dose, accessible for sleep improvement applications. |
SS-31 Is Now FDA-Approved. Here Is What That Means for the Anti-Aging Stack.
Most people running the GHK-Cu, Epithalon, SS-31 stack treat all three as research peptides in the same regulatory category. They are not. SS-31 (elamipretide) received FDA accelerated approval on September 19, 2025, under the brand name Forzinity, for improving muscle strength in patients with Barth syndrome. This makes it the first FDA-approved cardiolipin-directed mitochondrial therapeutic in US history, and the only FDA-approved compound in this stack.
The Barth syndrome approval was based on TAZPOWER (NCT03098797), a randomized controlled crossover trial in 12 patients with genetically confirmed Barth syndrome. The trial showed significant improvements in muscle strength and cardiac stroke volume over 168 weeks of open-label extension. A 2025 comprehensive review in International Journal of Molecular Sciences (Tung et al., PMC11816484) covers the full trial landscape for elamipretide, including the heart failure, macular degeneration, and primary mitochondrial myopathy trials.
The 2025 Aging Cell paper (PMC12151887) added important context for longevity applications: 8 weeks of elamipretide in aged C57BL/6J mice reduced frailty and improved cardiac strain and skeletal muscle fatigue resistance. But it did not reverse epigenetic age clocks or transcriptomic aging markers. SS-31 improves mitochondrial function without resetting your biological age score. That matters for how you think about its role in the stack. It addresses a real and significant mechanism of decline, but it is not a clock-resetter in the sense that some protocols imply.
Why SS-31 Works Where General Antioxidants Fail
Cardiolipin is a phospholipid found only in the inner mitochondrial membrane. It holds the electron transport chain complexes together in functional supercomplexes. As cardiolipin oxidizes with age, those supercomplexes disassemble, ATP synthesis efficiency drops, and cells across your body produce less energy. SS-31 binds directly to cardiolipin at the membrane interface, stabilizing its structure and restoring the electrochemical gradient the ATP synthase requires.
General antioxidants like CoQ10 and PQQ do not concentrate in the inner mitochondrial membrane at meaningful levels. SS-31 does, by design. A 2013 paper by Birk et al. in the Journal of the American Society of Nephrology showed that SS-31 re-energized ischemic mitochondria by specifically targeting the cardiolipin interface rather than broadly scavenging reactive oxygen species. That targeting is why it has produced results in disease populations where general antioxidants have consistently failed. MOTS-c targets a related mitochondrial pathway but through a different mechanism involving nuclear gene regulation rather than membrane structure.
What the Forzinity Approval Means for Off-Label Compounding Access
Here is the regulatory complication that has not fully reached the biohacking community: under FDA rules, compounding pharmacies generally cannot prepare a copy of a commercially available FDA-approved drug. Forzinity became commercially available from AnovoRx Specialty Pharmacy in December 2025. That means compounding SS-31 for off-label longevity use is now legally precarious in a way it was not when elamipretide was purely investigational. Some longevity clinics continue to source compounded elamipretide with off-label clinical justifications, but the legal exposure has increased significantly post-approval.
For people who want to use SS-31 within a clearly legal framework, the appropriate path is through a licensed physician who can justify clinical need against the approved indication or an investigational pathway. See the 2026 US peptide legal guide for the broader compounding access landscape. Gray-market vendor purchases of SS-31 are now more clearly outside the regulatory framework than before the approval.
The 12-Week Triple Stack Protocol: How to Sequence GHK-Cu, Epithalon, and SS-31
Most people run all three simultaneously on the assumption that more overlap means more anti-aging effect. That is not how this stack works. Epithalon is a pulse compound: its strongest telomere effects occur during and shortly after the 10-day cycle. Running it continuously does not add benefit. SS-31 produces functional improvements that plateau after 6-8 weeks without cycling. GHK-Cu has no known downregulation signal and works better with sustained continuous exposure.
The efficient approach: GHK-Cu as a continuous base layer throughout the year, Epithalon as a quarterly 10-day pulse, and SS-31 as two focused 6-8 week resets per year. Starting the SS-31 cycle in week 4 of the Epithalon quarter means GHK-Cu's gene activation program has had three weeks to establish a foundation of enhanced repair signaling before you layer mitochondrial optimization on top.
| Week | GHK-Cu | Epithalon | SS-31 |
|---|---|---|---|
| 1-10 | 1-3 mg/day subQ (or topical 0.25-1%) | 5-10 mg/day subQ (days 1-10 only) | Rest |
| 4-11 | Continue | Completed | 0.05-0.10 mg/kg/day subQ (weeks 4-11) |
| 12+ | Continue indefinitely | Next pulse: start of Q3 (July) | Second cycle: Q4 (October) |
The overlap in weeks 4-10, when SS-31 is running and Epithalon has completed, is intentional. There are no known pharmacokinetic interactions between the three peptides. GHK-Cu operates at the cell surface and extracellularly. Epithalon acts on pineal and nuclear signaling. SS-31 targets the inner mitochondrial membrane. The pathways are orthogonal, which is what makes the combination coherent in the first place.
Year-Round Protocol: What Comes After Week 12
After the first 12 weeks, GHK-Cu continues uninterrupted. Epithalon runs for 10 days each quarter: January, April, July, and October is a common schedule. SS-31 runs for 6-8 weeks twice per year. Winter timing for the first SS-31 cycle aligns with the period when mitochondrial function shows the most measurable decline in aging studies. A late summer or early fall cycle for the second supports recovery from the oxidative load that heat stress accumulates over summer months. These timing recommendations come from biological rhythm data and community protocol experience, not controlled trial evidence specifically on timing.
Which of the Three Clocks Is Running Fastest for You?
Not everyone ages at the same rate on all three pathways. Your genetics partially determines where you are most vulnerable and which peptide will produce the largest relative improvement from your current baseline.
For Epithalon: your TERT gene variants set your baseline telomerase activity. Lower-activity TERT variants mean your telomeres are shortening faster than average, giving Epithalon more room to produce a measurable effect. The hTERC variants that provide the RNA template telomerase uses to rebuild telomere ends are similarly predictive. If you have a family history of cardiovascular disease or certain cancers at younger ages, shorter baseline telomere length may be part of the story, and Epithalon becomes the highest-priority peptide in this stack. The 2025 Biogerontology paper confirmed that the 26-fold telomerase activation occurred most strongly in cells with the lowest baseline telomerase activity, consistent with a compensatory mechanism that responds most when there is the most room for improvement.
For GHK-Cu: the FOXO3 gene is one of the best-studied longevity genes in human population research. Specific FOXO3 alleles appear in centenarians at significantly higher rates than in the general population. Those same variants appear to predict stronger antioxidant and repair gene activation responses to interventions like GHK-Cu. NFE2L2 (NRF2) variants that reduce baseline antioxidant gene response may see a larger lift from GHK-Cu, since the peptide is activating pathways that were already underperforming. CYP3A4 metabolizer status matters less for GHK-Cu specifically but affects the overall pharmacokinetic context of your stack if you are running other compounds alongside it.
For SS-31: mitochondrial DNA haplogroup J, found in roughly 9 percent of European-ancestry individuals, is associated with increased electron leak at Complex I. That is the exact dysfunction SS-31 stabilizes. SOD2 variants that reduce mitochondrial superoxide clearance compound cardiolipin oxidation over time, increasing the degree of dysfunction SS-31 can address. Mitochondrial function decline also accelerates more sharply after 50 in people with nuclear DNA variants affecting mitochondrial biogenesis and maintenance. The MOTS-c article covers the related PGC-1 alpha pathway in more detail if mitochondrial genetics looks like your primary aging vulnerability. See also the DNA-first decision framework for a broader ranking of these genetic pathways before committing to a full three-compound protocol.
The 2026 anti-aging peptide review covers additional longevity compounds that complement this stack. The PeptidesDNA report analyzes your TERT, FOXO3, mitochondrial haplogroup, and NRF2 variants to rank these three clocks by their priority for your specific genotype. For some people, one clock is running significantly faster than the other two, and knowing which one allows you to front-load that peptide rather than spending on all three from week one.
Verdict: The GHK-Cu, Epithalon, and SS-31 stack is mechanistically well-founded, targeting three distinct aging pathways that do not overlap. The 2025 research updates strengthen the case for all three: Epithalon has its first independent Western confirmation of telomere extension in human cell lines, SS-31 has FDA approval and new aging-specific animal data showing functional improvement without epigenetic clock reversal, and GHK-Cu's regulatory path is opening after the April 2026 Category 2 removal. The sequencing matters: run GHK-Cu continuously, Epithalon in 10-day pulses four times per year, and SS-31 in two focused 6-8 week cycles annually. Your genetics determines which clock is running fastest, and prioritizing accordingly is more efficient than always starting with all three simultaneously. Upload your genetic data or order a saliva kit to identify your highest-priority aging pathway before committing to the full protocol. See the individual profiles at GHK-Cu and SS-31 for additional evidence summaries.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Can you take GHK-Cu, Epithalon, and SS-31 at the same time?
You can overlap them during certain phases, but the most efficient protocol staggers them deliberately. Epithalon works best in 10-day pulses and produces diminishing returns when run continuously. SS-31 reaches functional plateau after 6-8 weeks, after which cycling off is more cost-effective than continued dosing. GHK-Cu has no known downregulation signal and runs continuously as the base layer. The phased protocol in this article maximizes each peptide's mechanism without unnecessary exposure or cost overlap.
How long before you see results from this anti-aging stack?
The three peptides have different timelines. GHK-Cu improvements in skin texture and collagen density are often visible within 4-8 weeks of continuous use. SS-31 effects on energy levels and exercise capacity are typically reported within the first 2-4 weeks of a cycle, based on clinical trial data from disease populations. Epithalon's telomere effects are not directly visible, but users frequently report improved sleep quality during the 10-day cycle, consistent with the documented melatonin pathway effects. Long-term anti-aging effects require specific biomarker testing to measure and are not perceptible without monitoring.
Is SS-31 (elamipretide) legal to use for longevity?
SS-31 received FDA accelerated approval as Forzinity for Barth syndrome in September 2025. For longevity and anti-aging use, it is off-label. US compounding pharmacies now face legal restrictions on preparing copies of commercially available approved drugs, which Forzinity now is. Some clinics continue to compound SS-31 for off-label use with clinical justification, but the legal exposure has increased post-approval compared to when it was purely investigational. Gray-market vendor purchases fall outside the legal framework. A licensed physician is required to access it appropriately in the US.
Does Epithalon increase cancer risk by activating telomerase?
This is the main concern about Epithalon and it is a legitimate one to raise. Telomerase is the enzyme cancer cells use to escape programmed cell death. However, Russian long-term animal studies in cancer-prone mouse models consistently found fewer tumors, not more, in Epithalon-treated groups. The proposed explanation involves improved immune surveillance alongside telomerase activation, and possible epigenetic gating of the hTERT promoter that differs from cancer's uncontrolled activation. No long-term human safety RCT exists. The theoretical cancer concern has not materialized in available preclinical data, but human evidence is insufficient to rule it out definitively.
What is the difference between Epithalon and TA-65 for telomere extension?
TA-65 (cycloastragenol) activates telomerase through a different molecular pathway than Epithalon. TA-65 has more independent Western research supporting it. Epithalon has a 30-year institutional research record from the St. Petersburg Institute, with the 2025 Biogerontology paper now providing the first independent Western replication. The two have never been compared head-to-head in a clinical trial. They may be complementary since they appear to activate telomerase through distinct signaling mechanisms. Most longevity protocols that use both run them in separate cycles rather than simultaneously.
How do you know if this anti-aging stack is actually working?
There is no single test that captures all three mechanisms simultaneously. For SS-31, exercise capacity tests and subjective energy levels during a cycle are the most accessible proxies. For GHK-Cu, high-resolution ultrasound measurement of dermal collagen density is used in clinical trials but is rarely available in consumer settings. For Epithalon, commercial leukocyte telomere length testing (qPCR) can establish a baseline, though test-to-test variability is high. The most practical monitoring approach is tracking subjective markers, including sleep quality, recovery speed, skin texture, and energy, across a full 12-week cycle while keeping protocol variables constant.
Can women use this stack, and are there hormone-related considerations?
All three peptides operate through mechanisms that are identical in male and female biology. None are sex-specific compounds. Women going through perimenopause or post-menopause may notice GHK-Cu effects on skin particularly strongly, because estrogen decline accelerates collagen gene suppression, which GHK-Cu's gene modulation partially reverses. The Epithalon melatonin pathway effects may also be more noticeable in women whose circadian regulation has shifted with hormonal changes. There are no known interactions between these peptides and hormone replacement therapy, but this specific combination has not been formally studied.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.